Robust Call Option Activity Highlights Bullish Positioning
The most active call options for Sun Pharmaceutical Industries Ltd are concentrated at the ₹1800 strike price, with 2,749 contracts traded recently. This surge in activity has generated a turnover of approximately ₹21.58 crores, reflecting heightened market interest. Open interest stands at 4,843 contracts, indicating sustained bullish positioning ahead of the expiry date on 30 March 2026.
Given the underlying stock price of ₹1781.9, the ₹1800 strike calls are positioned near-the-money, suggesting traders anticipate a potential upside in the coming weeks. The concentration of call options at this strike price underscores confidence in the stock’s ability to breach or sustain levels above ₹1800, which would mark a significant milestone given its proximity to the 52-week high of ₹1851.2.
Price Performance and Technical Strength
Sun Pharma’s stock price has outperformed its sector by 0.68% on the day, registering a 1.92% gain, which is also well ahead of the Sensex’s 0.53% rise. The stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong upward trend and technical resilience. This technical backdrop supports the bullish sentiment reflected in the options market.
Investor participation has also surged, with delivery volumes reaching 38.54 lakh shares on 4 March 2026, marking an increase of 118.44% compared to the five-day average delivery volume. Such rising participation often precedes sustained price moves, as it indicates genuine accumulation rather than speculative trading.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Fundamental Strength and Market Capitalisation
Sun Pharmaceutical Industries Ltd is a large-cap company with a market capitalisation of ₹4,19,728 crores, firmly establishing its leadership within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score of 72.0 and an upgraded Mojo Grade from Hold to Buy as of 23 February 2026 reflect improved fundamentals and positive outlook from MarketsMOJO’s comprehensive analysis.
The upgrade was driven by enhanced earnings visibility, robust pipeline developments, and steady revenue growth, which have collectively improved the company’s quality and trend grades. The Market Cap Grade remains at 1, indicating the company’s dominant position in the market and its ability to attract institutional interest.
Expiry Patterns and Investor Sentiment
The expiry of options on 30 March 2026 is shaping up to be a critical juncture for Sun Pharma’s stock. The concentration of call options at the ₹1800 strike price, combined with rising open interest, suggests that investors are positioning for a potential breakout above recent highs. This is further supported by the stock’s proximity to its 52-week high, just 3.85% away, which acts as a psychological resistance level.
Options traders often use near-the-money call options to capitalise on expected upward price movements while limiting downside risk. The current data indicates that market participants are increasingly confident in Sun Pharma’s near-term prospects, possibly anticipating positive catalysts such as favourable regulatory developments, new product launches, or strong quarterly earnings.
Liquidity and Trading Viability
Liquidity remains robust for Sun Pharma, with the stock’s traded value supporting sizeable trade sizes up to ₹10.87 crores based on 2% of the five-day average traded value. This liquidity ensures that both institutional and retail investors can enter or exit positions efficiently without significant price impact, a crucial factor for active options traders.
The combination of strong liquidity, rising delivery volumes, and technical strength makes Sun Pharma an attractive candidate for both directional and hedging strategies in the options market.
Curious about Sun Pharmaceutical Industries Ltd from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Comparative Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, Sun Pharma’s outperformance relative to the sector’s 1.45% one-day return highlights its relative strength. The Sensex’s more modest 0.53% gain on the same day further emphasises Sun Pharma’s leadership among large-cap stocks.
Such outperformance is often a precursor to sustained momentum, especially when supported by strong fundamentals and positive market sentiment. Investors looking for exposure to the pharmaceutical space may find Sun Pharma’s current positioning appealing, given its blend of growth potential and defensive qualities.
Outlook and Investor Considerations
Sun Pharmaceutical Industries Ltd’s recent upgrade to a Buy rating by MarketsMOJO, combined with its strong call option activity, suggests a constructive outlook for the stock. Investors should monitor the upcoming expiry on 30 March 2026 closely, as the resolution of open interest at the ₹1800 strike price could trigger significant price movements.
While the stock is near its 52-week high, the technical and fundamental indicators support the possibility of further gains. However, investors should remain mindful of sector-specific risks such as regulatory changes, pricing pressures, and global pharmaceutical market dynamics.
Overall, the current market data and options activity point towards a bullish consensus, making Sun Pharma a key stock to watch in the near term.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
